Details for New Drug Application (NDA): 204242
✉ Email this page to a colleague
The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. There are twenty-nine drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.
Summary for 204242
Tradename: | ZUBSOLV |
Applicant: | Orexo Us Inc |
Ingredient: | buprenorphine hydrochloride; naloxone hydrochloride |
Patents: | 10 |
Pharmacology for NDA: 204242
Mechanism of Action | Opioid Antagonists Partial Opioid Agonists |
Suppliers and Packaging for NDA: 204242
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242 | NDA | Orexo US, Inc. | 54123-114 | 54123-114-30 | 3 BLISTER PACK in 1 CARTON (54123-114-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
ZUBSOLV | buprenorphine hydrochloride; naloxone hydrochloride | TABLET;SUBLINGUAL | 204242 | NDA | Orexo US, Inc. | 54123-907 | 54123-907-30 | 3 BLISTER PACK in 1 CARTON (54123-907-30) / 10 TABLET, ORALLY DISINTEGRATING in 1 BLISTER PACK |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;SUBLINGUAL | Strength | EQ 1.4MG BASE;EQ 0.36MG BASE | ||||
Approval Date: | Jul 3, 2013 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 18, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 18, 2032 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patented Use: | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Sep 18, 2032 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | USE OF ZUBSOLV FOR TREATMENT OF OPIOID DEPENDENCE |
Expired US Patents for NDA 204242
Complete Access Available with Subscription